A recent experimental study showed that a dual antagonist of both orexin receptors 1 and 2 attenuated neurogenic dural vasodilation and trigeminocervical complex activation and reduced susceptibility to KCl-evoked cortical spreading depression in animal models of migraine [35]. Here, HCRTR1 is linked to migraine disorder.